NP-1250, an ABCG2 inhibitor, induces apoptotic cell death in mitoxantrone-resistant breast carcinoma MCF7 cells via a caspase-independent pathway

Ito,Masumi; Kajino,Kazunori; Abe,Masaaki; Fujimura,Tsutomu; Mineki,Reiko; Ikegami,Takako; Ishikawa,Toshihisa; Hino,Okio

doi:10.3892/or.2013.2249

NP-1250, an ABCG2 inhibitor, induces apoptotic cell death in mitoxantrone-resistant breast carcinoma MCF7 cells via a caspase-independent pathway

Authors:
- Masumi Ito
- Kazunori Kajino
- Masaaki Abe
- Tsutomu Fujimura
- Reiko Mineki
- Takako Ikegami
- Toshihisa Ishikawa
- Okio Hino
View Affiliations

Affiliations: Department of Pathology and Oncology, Juntendo University School of Medicine, Bunkyo, Tokyo 113-8421, Japan, Laboratory of Proteomics and Biomolecular Science, Biomedical Research Center, Juntendo University Graduate School of Medicine, Bunkyo, Tokyo 113-8421, Japan, Laboratory of Molecular and Biochemical Research, Research Support Center, Juntendo University Graduate School of Medicine, Bunkyo, Tokyo 113-8421, Japan, Omics Science Center, RIKEN Yokohama Institute, Yokohama 230-0045, Japan
Published online on: January 24, 2013 https://doi.org/10.3892/or.2013.2249
Pages: 1492-1500

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemoresistance is one of the main obstacles to successful cancer therapy and is frequently associated with multidrug resistance (MDR). One of the most studied mechanisms of MDR is the high expression of ATP-binding cassette (ABC) transporters. Here, we demonstrated that NP-1250, an ABCG2 inhibitor, induced apoptotic cell death in ABCG2-overexpressing multidrug-resistant MCF7/mitoxantrone-resistant (MX) human breast carcinoma cells via a caspase-independent pathway. Incubation of MCF7/MX cells with NP-1250 significantly reduced cell viability, while NP-1250 had little effect on the viability of drug-sensitive MCF7/wild-type cells. Although the target molecules of NP-1250 in cell death remain unknown, investigation of NP-1250 will aid in the elucidation of the molecular mechanism of drug resistance and NP-1250 may become a new therapy for MDR cancers.

View Figures

View References

1	Scheffer GL, Maliepaard M, Pijnenborg AC, et al: Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res. 60:2589–2593. 2000.PubMed/NCBI
2	Kuo MT: Roles of multidrug resistance genes in breast cancer chemoresistance. Adv Exp Med Biol. 608:23–30. 2007. View Article : Google Scholar : PubMed/NCBI
3	Guo X, Ma N, Wang J, Song J, Bu X, Cheng Y, et al: Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer. 8:3752008. View Article : Google Scholar : PubMed/NCBI
4	Honma K, Iwao-Koizumi K, Takeshita F, Yamamoto Y, Yoshida T, Nishio K, et al: RPN2 gene confers docetaxel resistance in breast cancer. Nat Med. 14:939–948. 2008. View Article : Google Scholar : PubMed/NCBI
5	Katoh SY, Ueno M and Takakura N: Involvement of MDR1 function in proliferation of tumour cells. J Biochem. 143:517–524. 2008. View Article : Google Scholar : PubMed/NCBI
6	Chen Z, Liu F, Ren Q, Zhao Q, Ren H, Lu S, et al: Suppression of ABCG2 inhibits cancer cell proliferation. Int J Cancer. 126:841–851. 2010.PubMed/NCBI
7	Nakagawa M, Schneider E, Dixon KH, Horton J, Kelley K, Morrow C and Cowan KH: Reduced intracellular drug accumulation in the absence of P-Glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res. 52:6175–6181. 1992.PubMed/NCBI
8	Wakabayashi K, Nakagawa H, Adachi T, Kii I, Kobatake E, Kudo A and Ishikawa T: Identification of cysteine residues critically involved in homodimer formation and protein expression of human ATP-binding cassette transporter ABCG2: a new approach using the flp recombinase system. J Exp Ther Oncol. 5:205–222. 2006.
9	Saito H, Hirano H, Nakagawa H, Fukami T, Oosumi K, Murakami K, et al: A new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions. J Pharmacol Exp Ther. 317:1114–1124. 2006. View Article : Google Scholar
10	Wang T, Kajino K, Abe M, Tan K, Maruo M, Sun G, et al: Suppression of cell death by the secretory form of N-terminal ERC/mesothelin. Int J Mol Med. 26:185–191. 2010.PubMed/NCBI
11	Fujimura T, Shinohara Y, Tissot B, Pang PC, Kurogochi M, Saito S, et al: Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease of normal subjects. Int J Cancer. 122:39–49. 2008. View Article : Google Scholar : PubMed/NCBI
12	Janicke RU, Sprengart ML, Wati MR and Porter AG: Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem. 273:9357–9360. 1998. View Article : Google Scholar : PubMed/NCBI
13	Wilkinson B and Gilbert HF: Protein disulfide isomerase. Biochim Biophys Acta. 1699:35–44. 2004. View Article : Google Scholar : PubMed/NCBI
14	Keenan J, Murphy L, Henry M, Meleady P and Clynes M: Proteomic analysis of multidrug-resistance mechanisms in adriamycin-resistant variants of DLKP, a squamous lung cancer cell line. Proteomics. 9:1556–1566. 2009. View Article : Google Scholar : PubMed/NCBI
15	Liu Y, Liu H, Han B and Zhang JT: Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res. 66:3248–3255. 2006. View Article : Google Scholar : PubMed/NCBI
16	Montano MM, Ekena K, Delage-Mourroux R, Chang W, Martini P and Katzenellenbogen BS: An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Proc Natl Acad Sci USA. 96:6947–6952. 1999. View Article : Google Scholar : PubMed/NCBI
17	Zubovych I, Doundoulakis T, Harran PG and Roth MG: A missense mutation in Caenorhabditis elegans prohibitin 2 confers an atypical multidrug resistance. Proc Natl Acad Sci USA. 103:15523–15528. 2006.PubMed/NCBI
18	Shau H and Kim A: Identification of natural killer enhancing factor as a major antioxidant in human red blood cells. Biochem Biophys Res Commun. 199:83–88. 1994. View Article : Google Scholar : PubMed/NCBI
19	Kowaltowski AJ, Netto LE and Vercesi AE: The thiol-specific antioxidant enzyme prevents mitochondrial permeability transition evidence for the participation of reactive oxygen species in this mechanism. J Biol Chem. 273:12766–12769. 1998. View Article : Google Scholar
20	Chung YM, Yoo YD, Park JK, Kim YT and Kim HJ: Increased expression of peroxiredoxin II confers resistance to cisplatin. Anticancer Res. 21:1129–1133. 2001.PubMed/NCBI